Core Insights - Novartis (NVS) received a positive opinion from the CHMP of the EMA for remibrutinib, recommending marketing authorization for chronic spontaneous urticaria (CSU) treatment in adults unresponsive to H1 antihistamines, with a final decision expected in two months [1] Group 1: Product Approval and Market Potential - Remibrutinib, branded as "Rhapsido," was approved in the U.S. in September 2025 as the first FDA-approved oral Bruton's tyrosine kinase inhibitor (BTKi) for CSU, and it is also approved in China [2] - The CHMP's positive opinion is based on data from the REMIX-1 and REMIX-2 studies, which showed significant improvements in itch and hives, with sustained benefits through week 52, and a favorable safety profile [3][8] Group 2: Product Features and Additional Indications - Rhapsido is a selective oral BTK inhibitor aimed at reducing histamine release to alleviate CSU symptoms, and Novartis is exploring its use for other conditions, including chronic inducible urticaria and other immune-mediated diseases [4] - CSU affects approximately 40 million people globally, causing significant patient burden, including sleep disruption and mental health issues [5] Group 3: Competitive Landscape - Regeneron Pharmaceuticals and Sanofi received a positive opinion from the CHMP for expanding Dupixent's use in treating moderate-to-severe CSU in children aged 2 to 11 years, with a final decision expected soon [6] - The collaboration between Regeneron and Sanofi involves shared profits from global sales of Dupixent and Kevzara, indicating a competitive market for CSU treatments [7]

Summary of Jasper Therapeutics Data Update Webinar Company Overview - **Company**: Jasper Therapeutics (NasdaqCM:JSPR) - **Date of Call**: December 2, 2025 Key Points Industry and Company Focus - **Industry**: Biotechnology, specifically focusing on treatments for chronic spontaneous urticaria (CSU) and allergic asthma - **Core Product**: Briquilimab, a drug targeting mast cells BEACON Trial Findings - **Unexpected Results**: In the BEACON trial for CSU, none of the 10 U.S. patients in Cohort 8 achieved complete response by week 12, contrasting with two out of three patients in EU sites who did respond, indicating potential issues with drug lot A34954 used in the U.S. [4][5] - **Investigation**: An internal investigation was launched, reviewing manufacturing records, drug handling, and patient data. No significant deviations were found in drug production or handling [5][10][11]. - **Patient-Specific Factors**: The investigation concluded that patient-specific factors likely caused the unexpected results, with many patients possibly not having CSU [11][17]. Redosing Data from BEACON - **Cohorts 8 and 9**: Patients were switched to a new drug lot (34955) during the trial, showing no changes in pharmacokinetics (PK) or pharmacodynamics (PD) measures after redosing [12][15]. - **Clinical Outcomes**: The drug effectively depleted mast cells, as indicated by reduced tryptase levels, but clinical responses were not observed in many patients, suggesting misdiagnosis [15][17]. ATESIAN Study Results - **Study Design**: The ATESIAN trial assessed briquilimab's safety and efficacy in patients with mild allergic asthma, focusing on allergen challenges [20][21]. - **Efficacy Observations**: A single 180 mg dose resulted in significant reductions in serum tryptase levels and improved FEV1 responses, indicating a sustained effect on both early and late asthmatic responses [22][24]. - **Safety Profile**: Briquilimab was well tolerated with no serious treatment-related adverse events reported, reinforcing its safety in asthmatic populations [24][26]. Future Directions - **Next Steps**: Jasper plans to report additional BEACON data and open-label extension data in Q1 2026, including efficacy and safety data from new patients [26][27]. - **Broader Asthma Studies**: The company is evaluating further studies to explore briquilimab's effects across different asthma endotypes, including T2 high and T2 low diseases [25][27]. Recommendations for Future Trials - **Patient Selection**: Emphasis on quality patient selection is crucial, with recommendations to involve certified specialists in diagnosing CSU to avoid misdiagnosis [18][49]. - **Larger Sample Sizes**: Increasing sample sizes in trials may help mitigate the impact of non-mast cell-driven patients [18][67]. Conclusion - **Overall Outlook**: Jasper Therapeutics is optimistic about briquilimab's potential in treating both CSU and asthma, with ongoing investigations and upcoming data expected to support its clinical efficacy and safety [72].

Core Insights - Novartis announced FDA approval for Rhapsido (remibrutinib) as the first oral treatment for chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite H1 antihistamine treatment [2][5][9] - Rhapsido is a twice-daily pill that targets Bruton's tyrosine kinase (BTK) to inhibit histamine release, providing a new treatment option for CSU patients [2][6][7] Company Developments - The approval is based on Phase III clinical trials (REMIX-1 and REMIX-2), showing Rhapsido's superiority in reducing itch and hives compared to placebo [6][8] - Rhapsido demonstrated a safety profile that does not require lab monitoring, with common adverse events including nasal congestion and headache [8] - Novartis is expanding its immunology portfolio with Rhapsido, which is also in development for other conditions like chronic inducible urticaria and food allergies [7][9] Industry Context - CSU affects approximately 1.7 million people in the US, with over half remaining symptomatic despite antihistamine treatment [7] - The approval of Rhapsido represents a significant advancement in CSU care, offering patients a convenient oral option that can improve their quality of life [5][9] - The treatment landscape for CSU has been limited, with many patients feeling underserved by existing therapies [5][4]